BioPharma Dive

MAY 4, 2023

After issues with a contract research group, the partners now expect to file an approval application for their shot in 2026, one year later than initially anticipated.

Vaccines 126

Vaccines 126

Express Pharma

JANUARY 22, 2024

Cameroon has kickstarted the world’s first routine vaccine programme against malaria. It is one of 20 African countries planning to introduce the drug this year, according to global vaccine alliance Gavi. The vaccine is designed to be administered to young children in four doses from around five months of age.

Vaccines 105

Vaccines 105

Pharmacy Times

APRIL 2, 2025

The only major change is in the included strain of influenza A/H2N2 virus, which has been updated for both the egg-based and the cell- and recombinant-based vaccines.

Vaccines 49

Vaccines 49

BioPharma Dive

OCTOBER 9, 2023

The purchase agreement with Chongqing Zhifei Biological Products is part of GSK’s plan to double sales of the shingles vaccine by 2026.

Vaccines 111

Vaccines 111

BioPharma Dive

OCTOBER 24, 2024

As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.

Vaccines 57

Vaccines 57

Pharmaceutical Technology

JULY 18, 2022

GlaxoSmithKline (GSK) has signed an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to aid in protecting adults and children in the country. The company intends to supply both vaccines from its 230,000ft² Sainte-Foy facility in Quebec. .

Vaccines 64

Vaccines Immunization Immunity 64

Pharmaceutical Technology

NOVEMBER 24, 2022

South African bio-pharmaceutical firm Biovac and the International Vaccine Institute (IVI) in South Korea have signed a licencing and technology transfer agreement for developing and manufacturing an oral cholera vaccine (OCV).

Vaccines 59

Vaccines Packaging 59

Pharmaceutical Technology

JUNE 2, 2023

The European Commission (EC) and Pfizer/BioNTech have agreed to amend their current supply contract to deliver Covid-19 vaccines to the EU. More significantly, the revised contract secures about 70 million vaccine doses every year from 2023 to 2026 for member states, leaving little space in the market for competitors.

Vaccines 52

Vaccines 52

European Pharmaceutical Review

JULY 6, 2023

Further trials will be launching although most patients are expected to be enrolled from 2026 onwards. The Cancer Vaccine Launch Pad (CVLP), a new partnership led by NHS England, will create a database of eligible NHS cancer patients who will be offered the choice to take part in personalised cancer vaccine trials.

Vaccines 98

Vaccines 98

European Pharmaceutical Review

SEPTEMBER 22, 2023

Aseptic packaging eliminates the necessity for preservatives and refrigeration which is especially advantageous for medications and vaccines that are sensitive to temperature changes. Research Nester highlighted statistics which acknowledged that European production of pharmaceutical aseptic packaging is expected to reach $56 billion by 2026.

Packaging 105

Packaging Vaccines Compounding 105

Express Pharma

MARCH 20, 2023

India is preparing to include human papillomavirus (HPV) vaccines as part of the government-driven public immunization program popularly known as the Universal Immunization Program (UIP). The Indian government will float a global tender in April 2023 to procure HPV vaccines. per cent from 0.43 million in 2021 to 0.54 million in 2030.

Vaccines 52

Vaccines Immunity Immunization 52

Pharmaceutical Technology

SEPTEMBER 23, 2022

It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. Additionally, Merck has signed patent litigation settlement deals with various generic firms, permitting them to offer generic versions of Januvia and Janumet to the US market in May 2026, or before under specific conditions.

Vaccines 69

Vaccines 69

FDA Law Blog: Biosimilars

FEBRUARY 4, 2025

With the current lapse in authorization, FDA may only award RPD PRVs for applications that have received an RPD designation before December 20, 2024, andunless reauthorized before thenmay not award any RPD PRVs after September 30, 2026. Below, we discuss some of its downstream impacts on the PRV landscape.

Vaccines 52

Vaccines 52

pharmaphorum

APRIL 29, 2022

The healthy sales increase was bolstered by the timing of orders for AZ’s COVID-19 vaccine Vaxzevria , which made $1.1 “Our combined company has already successfully leveraged internal scientific synergies, and this move will act as a catalyst for even more external collaboration and innovation,” he added.

Diabetes 111

Diabetes Vaccines 111

pharmaphorum

SEPTEMBER 30, 2022

That challenged the ‘708 patent – which expires in November 2026 – as well as one other (No. Viatris could still take its cases further, but for now Merck has retained market exclusivity for Januvia, Janumet, and Janumet XR until at least 2026. billion in the first half of 2022.

Diabetes 59

Diabetes Vaccines 59

pharmaphorum

OCTOBER 28, 2021

The Association of the British Pharmaceutical Industry (ABPI) and BioIndustry Association (BIA) both said that the increase acknowledges the enormous contribution made by the life sciences sector in helping to limit the impact of the pandemic through the rapid development of diagnostics, drugs and vaccines.

Pharmaceutical Manufacturing 111

Pharmaceutical Manufacturing Vaccines 111

European Pharmaceutical Review

AUGUST 22, 2022

They noted that while production of COVID-19 pandemic vaccines and therapeutics is currently absorbing much of the flexible capacity available in the industry, but said that as demand moderates, capacity will normalise enabling other products to be prioritised.

Vaccines 98

Vaccines 98

pharmaphorum

NOVEMBER 6, 2022

The new drug will reach the market ahead of RSV vaccines that are designed to protect newborns in the months after birth by vaccinating expectant mothers, who pass on antibodies against the virus in the womb. AZ and Sanofi say they hope to launch the antibody next autumn, in time for the 2023/24 RSV season.

Vaccines 64

Vaccines Labelling 64

Express Pharma

NOVEMBER 24, 2023

A vaccine manufacturing powerhouse, India leads by supplying over 60 per cent of global vaccine demand. The future involves a growing production capacity, collaboration with private players, and a commitment to training 30 million professionals in digital skills by 2026.”

Packaging 105

Packaging Vaccines Pharmaceutical Manufacturing Hospitals 105

Pharmaceutical Technology

JULY 28, 2022

Tuas Biomedical Park New Vaccine Production Facility – $467m. The project involves the construction of a new vaccine production facilities at Tuas Biomedical Park in Singapore. Construction work started in Q2 2022 and is expected to be completed in Q1 2026. Yeosu Mononitrobenzene Manufacturing Plant – $375m.

Vaccines 52

Vaccines 52

pharmaphorum

JUNE 15, 2021

New Science is projected to drive 81% of biopharma revenue growth and 61% of all revenues between 2021 and 2026, outpacing our previous forecast of 54% of all revenues from 2017-2022. And we expect a 69% higher average net present value (NPV) for New Science treatments versus traditional counterparts from 2022—2026.

Vaccines 90

Vaccines 90

pharmaphorum

JANUARY 29, 2023

Think about recent technological breakthroughs such as mRNA vaccines and the potential for mRNA-based therapeutics, or the recent ramp up in vaccine production facilities – to name just a few examples. That’s what is relentlessly driving industry growth, as well as spurring innovation and efficiency.

Nursing Homes 98

Nursing Homes Hospitals Vaccines 98

Big Molecule Watch

DECEMBER 13, 2024

Sanofis opens new modular vaccine and biopharmaceutical facility in Singapore, its first facility of this type outside France On November 27, 2024, Sanofi announced and launched a 800 million SGD ($595 million) modular vaccine and biopharmaceutical facility in Singapore, its first modular vaccine facility outside France.

Vaccines 45

Vaccines Immunity Immunization 45

pharmaphorum

APRIL 21, 2022

Overall spending on medicines rose 12% in 2021 to $407 billion, driven by a $29 billion spend on COVID-19 vaccines and medicines. Prescription drug use in the US soared last year, as might be expected during a pandemic, but is expected to fall back sharply in 2023, according to IQVIA’s latest report on the sector.

Vaccines 52

Vaccines Biosimilars 52

Pharmaceutical Technology

JULY 28, 2022

Tuas Biomedical Park New Vaccine Production Facility – $467m. The project involves the construction of a new vaccine production facilities at Tuas Biomedical Park in Singapore. Construction work started in Q2 2022 and is expected to be completed in Q1 2026. Yeosu Mononitrobenzene Manufacturing Plant – $375m.

Vaccines 40

Vaccines 40

Putting Patients First Blog

SEPTEMBER 20, 2024

The legislation included multiple provisions related to Medicare drug coverage including a $2000 cap on out-of-pocket drug costs, a $35/month insulin cap, and improved access to adult vaccines. A feature of the legislation that continues to receive widespread attention is the Medicare Drug Price Negotiation Program (MDPNP).

Drug Pricing 52

Drug Pricing Communication Vaccines 52

pharmaphorum

FEBRUARY 7, 2022

The approval is some relief for Sanofi after a crop of pipeline disappointments last year, with Evaluate estimating the drug could make more than $500 million in sales in 2026. It also abandoned an mRNA-based vaccine for COVID-19 and suffered delays to another COVID-19 shot partnered with GlaxoSmithKline.

Labelling 52

Labelling Immunity Immunization Vaccines 52

RX Note

FEBRUARY 4, 2024

Additionally, pharmacists in many countries, including the United States, UK and Australia, are empowered to administer vaccines, improving accessibility and reducing healthcare system strain. Most community pharmacies routinely provide preventive services like blood pressure, glucose and lipid screenings.

Community Pharmacies 52

Community Pharmacies Medical Records Compounding Diabetes 52

pharmaphorum

JULY 1, 2021

Along with the appointment of new non-executive directors, Elliott would like to see a moratorium on profit and revenue-related bonuses unless management meets its 2026 targets of 5% profit growth and 10% turnover growth and raising the margin target from 30% to 32%.

Vaccines 52

Vaccines 52

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

On November 17th, CMS issued its final guidance on the Discount Program in which it responded to public comments and provided updated guidance for the Discount Program for 2025 and 2026. covered insulin product or vaccine). Manufacturers must sign the agreement by March 1, 2024, to participate in the 2025 plan year.

Labelling 105

Labelling Drug Pricing Compounding Payment Processing 105

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth.

HIV Treatment and Prevention Agents 59

HIV Treatment and Prevention Agents Vaccines Pharmaceutical Companies Pharmaceutical Companies 59

Viseven

SEPTEMBER 18, 2024

The rest is history: vaccines were delivered worldwide in record time, saving millions of lives. By the end of 2026, the company will be able to analyze two million genomes. This quick reporting helped the CDC gather crucial data on the vaccine’s effectiveness, contributing to its further improvements.

Communication 52

Communication Vaccines Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JANUARY 21, 2022

And as with many healthcare challenges, it is an issue that has been brought into sharp focus by COVID-19, during which we have seen huge investments in ground-breaking vaccines, quickly followed by inequities in access. There is no easy answer to the question of how to incentivise innovation without restricting access.

Vaccines 52

Vaccines 52

Express Pharma

JANUARY 12, 2024

Initiatives such as Ayushmaan Bharat Digital Mission (“ADBDM”), CoWIN (a digital vaccine delivery platform), health registry, and telemedicine, highlight the government’s strong emphasis on digitisation of health in India. Expectation #4 Clarification on product samples and low brand value items – According to CBDT circular no.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Pharmaceutical Companies Pharmaceutical Companies Health Insurance Companies 52

PharmaShots

FEBRUARY 21, 2023

threshold by 2026. Under its cancer therapy products, the company develops low molecular drugs, antibody drugs, cancer peptide vaccines, and diagnostic medicines. With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the market.

Dosage 56

Dosage Labelling Immunity Immunization 56

pharmaphorum

FEBRUARY 16, 2022

The Life Sciences Vision also identified seven therapeutic areas that are priorities for the government: treatments for neurodegenerative disorders, cancer immunotherapies, novel vaccines, cardiometabolic therapies, treatments for respiratory disorders, therapies for multi-system ageing and treatments for mental illness.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

pharmaphorum

JANUARY 6, 2022

IQVIA Institute models global cumulative spend on COVID-19 vaccines to be a base case of $251bn to 2026 , with spend on COVID-19 treatments, including the new oral agents and treatments of post-viral syndromes, likely to add significant incremental spend. Medicine budget constraint, structural fund largesse.

Vaccines 111

Vaccines Pharmaceutical Companies Pharmaceutical Companies 111